重新评估侵袭性曲霉病等侵袭性真菌病的联合抗真菌治疗
侵袭性曲霉病死亡率仍高,一线三唑类药物耐药上升。作者评述既往伏立康唑联合阿尼芬净与伏立康唑单药随机对照试验,认为联合方案安全且全因死亡率有临床显著下降但未达传统显著性,主张综合实验室与临床证据支持三唑类联合棘白菌素用于免疫抑制患者。
要点
- 侵袭性曲霉病死亡率仍高,一线三唑类耐药上升使治疗受挑战。
- 伏立康唑联合阿尼芬净安全,全因死亡率下降但未达传统显著性。
- 综合证据支持三唑类联合棘白菌素用于免疫抑制患者的确诊或临床诊断侵袭性曲霉病。
核心结论
- 作者反对对联合治疗试验结果作二元阴性解读,认为综合实验室与临床证据支持三唑类联合棘白菌素治疗免疫抑制患者的确诊或临床诊断侵袭性曲霉病。
- 需重新努力优化和评估曲霉病及其他危及生命的侵袭性真菌病的其他联合方案,以减轻耐药、最大化并延长新旧药物效用并降低死亡率。
研究设计与样本
- 本文为Personal View,评述既往伏立康唑联合阿尼芬净对比伏立康唑单药的随机对照试验结果。
主要发现
- 既往随机对照试验显示伏立康唑联合阿尼芬净安全,并与全因死亡率有临床显著下降相关,但未达传统显著性水平。
- 侵袭性曲霉病死亡率仍不可接受地高,一线三唑类药物耐药上升对当前推荐治疗构成挑战。
临床怎么用
- 对免疫抑制的确诊或临床诊断侵袭性曲霉病患者,可依据综合证据考虑三唑类联合棘白菌素治疗。
- 应继续优化和评估其他联合方案,以应对耐药并降低侵袭性真菌病死亡率。
局限性
- 本文为Personal View观点性文章,非原始研究,未提供新的随机对照试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mortality from invasive aspergillosis remains unacceptably high, and the currently recommended treatment of triazoles is further challenged by rising resistance to these first-line agents. A previous randomised controlled trial of combination therapy with voriconazole plus anidulafungin versus voriconazole alone showed that the combination was safe and associated with a clinically significant reduction in all-cause mortality that, however, failed narrowly to meet conventional levels of significance. In this Personal View, we argue against a binary, negative interpretation of these results, and that the totality of the laboratory and clinical evidence favours a triazole-echinocandin combination for the treatment of immunocompromised patients with proven or probable invasive aspergillosis. Renewed efforts are needed to optimise and evaluate other combination approaches for aspergillosis and other life-threatening invasive fungal diseases as a means by which to mitigate antifungal resistance, maximise and prolong the utility of old and new agents, and drive down mortality.
引用
- Harrison TS, Walsh TJ. Time to re-evaluate combination antifungal therapy for invasive aspergillosis and other invasive mycoses. Lancet Infect Dis. 2026. PMID: 41655591. doi:10.1016/S1473-3099(26)00004-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。